Nelfinavir's Effect on Iron Metabolism in Breast Cancer ID: 2022-029
This study reveals Nelfinavir's potential as a therapeutic agent in breast cancer by targeting iron metabolism.
Photo by Bangkok Click Studio And Space
Technology Overview
The document examines the impact of Nelfinavir, an HIV protease inhibitor, on iron metabolism in MCF-7 breast cancer cells. It focuses on Nelfinavir's ability to decrease hepcidin levels and increase ferroportin presence, thus reducing iron accumulation in cancer cells and potentially impairing their growth.
Key Advantages
- Decreases hepcidin levels, reducing iron sequestration in cancer cells
- Increases ferroportin presence, facilitating iron export from tumorigenic cells
- Demonstrates selective effects on cancer cells without harming normal cells
- Potentially increases survival by mitigating anemia and tumor progression
Problems Addressed
- Reduces the metabolic advantage of cancer cells through iron sequestration
- Addresses the anemia of cancer by stabilizing systemic iron homeostasis
- Provides an alternative to therapies that may promote cancer growth
Market Applications
- Treatment for breast cancer by targeting iron metabolism
- Potential application in other cancers utilizing hepcidin for ferroportin suppression, such as prostate cancer
- Novel therapeutic approach in oncology to address anemia of cancer
Additional Information
Technology ID: 2022-029
Sell Sheet: Download the Sell Sheet here
Market Analysis: Contact us for a more in-depth market report
Date Published: 28 March, 2025
Connect with the Tech Transfer to:
- Meet with the technology manager
- Receive additional information
- Request a marketing plan report